Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)

被引：2
|
作者：
Lancet, Jeffrey E. [1 ]
Komrokji, Rami S. [1 ]
Sweet, Kendra L. [1 ]
Duong, Vu H. [2 ]
McGraw, Kathy L. [1 ]
Zhang, Ling [3 ]
Nardelli, Lisa Ann [1 ]
Ma, Zhenjun [4 ]
Reich, Richard R. [5 ]
Padron, Eric [1 ,6 ]
List, Alan F. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[2] Univ Maryland Sch Med, Dept Med, Baltimore, MD USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Hematopathol & Lab Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist & Bioinformat, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist & Bioinformat, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3174.3174
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3174
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Heuser, Michael
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Fernandez, Pau Montesinos
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    BLOOD, 2016, 128 (22)
  • [22] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Borate, U.
    Smith, B. D.
    Gore, S.
    Zeidan, A.
    Savona, M.
    Savoie, M. L.
    Zhu, N.
    Breems, D.
    Zhang, X.
    Shaik, M. N.
    Rampersad, A.
    Chan, G.
    Woolfson, A.
    Sekeres, M.
    HAEMATOLOGICA, 2016, 101 : 73 - 74
  • [23] Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients
    Flinn, Ian W.
    Lang, Evan
    Raefsky, Eric
    Boccia, Ralph
    Macias-Perez, Ines M.
    Burris, Howard A., III
    Hainsworth, John D.
    BLOOD, 2010, 116 (21) : 1636 - 1637
  • [24] Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial
    Zeidan, Amer M.
    Zeidner, Joshua F.
    Duffield, Amy
    Knaus, Hanna A.
    Ferguson, Anna
    Sheldon, Katherine
    DeZern, Amy E.
    Gojo, Ivana
    Gore, Steven D.
    Streicher, Howard
    Luznik, Leo
    Smith, B. Douglas
    BLOOD, 2015, 126 (23)
  • [25] Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial
    Garcia-Manero, Guillermo
    Adema, Vera
    Urrutia, Samuel
    Ma, Feiyang
    Yang, Hui
    Ganan-Gomez, Irene
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas
    Issa, Ghayas C.
    Chien, Kelly S.
    Montalban-Bravo, Guillermo
    Joseph, Joby
    Colla, Simona
    BLOOD, 2022, 140 : 2078 - 2080
  • [26] PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients
    Papayannidis, Cristina
    Guadagnuolo, Viviana
    Iacobucci, Ilaria
    Durante, Sandra
    Terragna, Carolina
    Ottaviani, Emanuela
    Abbenante, Maria Chiara
    Cattina, Federica
    Soverini, Simona
    Lama, Barbara
    Toni, Lucia
    Levin, Wendy J.
    Courtney, Rachel
    Baldazzi, Carmen
    Curti, Antonio
    Baccarani, Michele
    Jamieson, Catriona
    Cortes, Jorge E.
    Oehler, Vivian
    McLachlan, Karen
    Van Arsdale, Todd
    Martinelli, Giovanni
    BLOOD, 2011, 118 (21) : 620 - 621
  • [27] PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients
    Papayannidis, Cristina
    Guadagnuolo, Viviana
    Iacobucci, Ilaria
    Durante, Sandra
    Terragna, Carolina
    Ottaviani, Emanuela
    Abbenante, Maria Chiara
    Cattina, Federica
    Soverini, Simona
    Lama, Barbara
    Toni, Lucia
    Levin, Wendy
    Courtney, Rachel
    Baldazzi, Carmen
    Curti, Antonio
    Baccarani, Michele
    Jamieson, Catriona
    Cortes, Jorge
    Oehler, Vivian
    McLachlan, Karen
    VanArsdale, Todd
    Martinelli, Giovanni
    CANCER RESEARCH, 2012, 72
  • [28] Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies
    Reddy, Nishitha
    Voorhees, Peter M.
    Houk, Brett E.
    Brega, Nicoletta
    Hinson, James M., Jr.
    Jillela, Anand
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 385 - 391
  • [29] Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
    Venugopal, Sangeetha
    DiNardo, Courtney D.
    Takahashi, Koichi
    Konopleva, Marina
    Loghavi, Sanam
    Borthakur, Gautam
    DeZern, Amy
    Masarova, Lucia
    Daver, Naval
    Short, Nicholas J.
    Alvarado, Yesid
    Ravandi, Farhad
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Delumpa, Ricardo
    Sekeres, Mikkael A.
    Patel, Bhumika
    Roboz, Gail J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S339 - S339
  • [30] Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).
    Venugopal, Sangeetha
    Dinardo, Courtney Denton
    Takahashi, Koichi
    Konopleva, Marina
    Loghavi, Sanam
    Borthakur, Gautam
    Dezern, Amy Elizabeth
    Masarova, Lucia
    Daver, Naval Guastad
    Short, Nicholas James
    Alvarado, Yesid
    Ravandi, Farhad
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Delumpa, Ricardo
    Sekeres, Mikkael A.
    Patel, Bhumika J.
    Roboz, Gail J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345